-- 周三，浑水研究公司（Muddy Waters Research）和卡利斯托研究公司（Callisto Research）发布做空Sportradar集团（SRAD）的报告后，该公司股价暴跌超过23%。 浑水研究公司的报告称，Sportradar“积极协助并教唆全球黑市和灰色市场的非法赌博活动——这并非偶然或疏忽，而是其商业策略”。该公司估计，目前非法运营商的收入约占其总收入的20%至40%。 同样做空Sportradar的卡利斯托研究公司表示，通过对数百个赌博平台的调查，该公司发现有证据表明，超过270个平台正在使用Sportradar的产品或服务，或明确声称正在使用，而“这些平台在受监管或被禁止的赌博市场中非法运营”。该公司还补充说，其中相当一部分运营商根本没有任何许可证。 Sportradar尚未回复的置评请求。
Price: $12.09, Change: $-4.76, Percent Change: -28.24%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.